TrialAnnals of oncology : official journal of the European Society for Medical Oncology2025

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.

J N Graff et al.PubMed ↗Publisher ↗

No numbers read from the abstract.